2-deoxy-d-glucose (2-DG) was used to modulate the glucose metabolism in CML cells sensitive to IM (KBM5 cell line) and resistant to imatinib with BCR-ABL T315I mutation (KBM5-T315I cell line). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.